|
Accumulated capitals
|
- Development of new technologies and products that meet consumer needs and preferences at the R&D sites of each business, along with continuous accumulation of intellectual capital
|
- Optimization of supply through long-term relationship building with tobacco leaf growers, dealers, and various suppliers over many years (social and relationship capital)
- Realization of stable, cost-competitive procurement of high-quality ingredients (natural capital)
|
- Global production system (manufacturing capital) for stable manufacturing of high-quality products that meet consumer needs
- Inspection program that ensures high quality standards
|
- Strong brand equity (intellectual capital) of product groups to support provision of products that meet consumer and patient needs
- Thorough compliance with marketing-related laws, regulations, and guidelines for products provided in the tobacco and pharmaceutical businesses
|
- Developing sales strategies based on strong relationships with distributors, tobacconists, and medical institutions (social and relationship capital)
- Building of distribution networks optimized for consumer needs and adapted to the business environment
|
|
Strengths and characteristics
|
-
●
-
Globally integrated R&D structure with outcome-based, consumer-centric approaches
-
●
-
Over 2,000 IP filings, diverse innovation partnership with third-party players
-
●
-
High-level small molecule drug discovery capabilities
-
●
-
Proprietary yeast-related, processing and freezing technologies
|
-
●
-
Diversified leaf supply across vertically integrated operations and third parties, ensuring reliability regardless of weather or market fluctuations
-
●
-
Advanced planning and inventory management for uninterrupted manufacturing
-
●
-
Inspection and audit programs for ingredient safety
|
-
●
-
Global footprint, state-of-the-art equipment and manufacturing processes, with industry-leading quality standards for all our products
-
●
●
●
-
Ensuring product quality and safety in line with laws and regulations, and international standards
|
-
●
-
Strong brand equity, notably Winston, Camel, MEVIUS and LD, supported by focused investment
-
●
-
Consumers at center of our offerings: we provide freedom of choice and superior quality
-
●
-
Multiple leading brands by market share in Japan
|
-
●
-
Global sales network with tailored RTC for each market, and motivated salesforce with strong ties with trade
-
●
-
Responsible sales information provision system based on guidelines
-
●
-
Product proposal capabilities to meet consumer needs with a rich product lineup
|
|
Initiatives for increasing added value
|
-
●
-
Accelerating the development of new RRP platforms
-
●
-
Protecting innovation with sound IP strategy
-
●
-
Improvement of R&D productivity
-
●
-
Establishment of proprietary drug discovery technology
-
●
-
Development of new products considering environmental impact and sustainability
|
-
●
-
Further enhancing and adapting the RRP sourcing strategy to be more resilient and avoid disruptions
-
●
●
●
-
Increasing emphasis on social and environmental sustainability of supply
-
●
-
Continuously balancing risk mitigation and sourcing flexibility
|
-
●
●
●
-
Constantly reviewing and optimizing manufacturing footprint, while improving manufacturing processes
-
●
-
Expansion of RRP production capacity through continuous investment
-
●
●
-
Accelerating our environmental impact reduction initiatives to meet Group targets
|
-
●
●
●
-
Strengthening product proposal capabilities and sales strategies through understanding of consumer and patient needs
-
●
●
●
-
Continuous investment in brand equity across the business, notably Ploom in the tobacco business
-
●
-
Continuous deployment of youth access prevention strategies
-
●
●
-
Expanding capabilities in areas of digital, advanced analytics and B2C
|
-
●
●
-
Regularly evaluating new market entries and channels for profitability, while optimizing RTC based on the evolving environment
-
●
●
-
Disclosure of product information on websites and product packaging
-
●
-
Building stronger relationships with key distributors and tobacconists, while enhancing e-commerce capabilities in markets where nicotine and tobacco products e-commerce is legally allowed
|
